Could a glaucoma eye drop also heal the cornea?

NCT ID NCT06960629

Completed Disease control Sponsor: University Hospital Dubrava Source: ClinicalTrials.gov ↗

First seen Jul 01, 2026 · Last updated Jul 29, 2026 · Updated 5 times

Summary

This study tests whether a combination eye drop (netarsudil/latanoprost) can improve vision and reduce corneal thickness in people with glaucoma and a condition called pseudophakic bullous keratopathy, where the cornea swells after cataract surgery. Half of the 50 participants receive the active drops once daily for three months, while the other half receive placebo artificial tears. Researchers measure visual acuity and corneal thickness every two weeks to see if the drug helps.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Netarsudil/latanoprost eye drops
What this could lead to: If effective, these eye drops could offer a non-surgical way to improve vision and reduce corneal swelling in patients with glaucoma and pseudophakic bullous keratopathy.
What could go wrong: This is a small, early-stage trial with only 50 participants. The treatment may not prove better than placebo, and eye drops can cause irritation or redness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLAUCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bullous keratopathy corneal edema glaucoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLAUCOMA PSEUDOPHAKIC BULLOUS KERATOPATHY

Contacts and locations

Locations

University Hospital Dubrava

Zagreb, Croatia, 10000, Croatia

More trials for these conditions

Other studies related to the condition(s) this trial covers.